Inhibition of tumor growth with lower DOX dosage, reduced cardiotoxicity upon activation of Nrf2; Reduction in tumor volume, increase in cytotoxic CD8+T cells, decrease in MDSC population with subsequent immunosuppression. The gene discussed is CD8A; the disease is neoplasm.